About ADL

This author has not yet filled in any details.
So far ADL has created 32 blog entries.

Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma

By |2020-07-20T17:10:02+00:00July 20th, 2020|

DALLAS, TX – JULY 20, 2020 – Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced entering into agreements with leading contract manufacturing companies [...]

5 DALLAS BIOTECH COMPANIES TURNING THE LONE STAR STATE INTO A LIFE SCIENCES LEADER

By |2020-07-20T15:08:48+00:00July 6th, 2020|

Despite its association with rodeos, barbeque and live music, Texas has seemingly shirked its Western persona in recent years to take a leap into the tech industry. Each of the state’s top tech hubs — Austin, Houston and Dallas — has cultivated its own unique tech culture, leading to the rise of various sectors including biotech.

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Datapoints, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Datapoints Curated Specifically for Oncology Drug Development and Drug Response Prediction

By |2020-07-08T16:34:30+00:00June 29th, 2020|

DALLAS, TX – JUNE 29, 2020 – Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 [...]

Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting

By |2020-07-08T16:40:10+00:00June 17th, 2020|

Lantern Pharma to update leading cancer researchers and healthcare professionals on use of artificial intelligence to accelerate development of precision cancer therapies DALLAS, June 17, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process [...]

Lantern Pharma Announces Closing of Initial Public Offering

By |2020-07-08T16:39:14+00:00June 15th, 2020|

DALLAS, June 15, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, today announced the closing of its initial [...]

Lantern Pharma Announces Pricing of Initial Public Offering

By |2020-07-08T16:40:48+00:00June 10th, 2020|

DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, today announced the pricing of its initial public [...]

Dallas biotech company files to go public as it works to help beat cancer

By |2020-07-08T23:41:53+00:00April 16th, 2020|

A Dallas biotech company tapping into artificial intelligence has filed to go public. Lantern Pharma Inc., which is working on a treatment for cancer, filed an S-1 on Thursday with the U.S. Securities and Exchange Commission. It’s pre-revenue and posted a loss of more than $2 million last year.